NewAmsterdam Pharma (NASDAQ:NAMS – Get Rating) – Research analysts at William Blair issued their FY2027 earnings per share estimates for NewAmsterdam Pharma in a research report issued to clients and investors on Monday, January 23rd. William Blair analyst M. Phipps expects that the company will earn ($0.16) per share for the year. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is $0.27 per share.
Get NewAmsterdam Pharma alerts:Several other research analysts also recently commented on the company. Credit Suisse Group began coverage on NewAmsterdam Pharma in a research note on Friday, January 6th. They issued an "outperform" rating and a $21.00 target price for the company. Jefferies Financial Group initiated coverage on NewAmsterdam Pharma in a research report on Monday, December 19th. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, SVB Leerink assumed coverage on NewAmsterdam Pharma in a research report on Tuesday, December 20th. They issued an "outperform" rating and a $19.00 price objective on the stock.
NewAmsterdam Pharma Stock Up 20.0 %
Shares of NewAmsterdam Pharma stock opened at $13.56 on Thursday. NewAmsterdam Pharma has a 1 year low of $7.52 and a 1 year high of $32.88. The company's fifty day simple moving average is $10.37.NewAmsterdam Pharma Company Profile
(Get Rating)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein inhibitor that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events.
Recommended Stories
- Get a free copy of the StockNews.com research report on NewAmsterdam Pharma (NAMS)
- Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
- The Future Of E-Commerce: Analysis And New Data
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.